Carnitine Infusion and Insulin Resistance

• ClinicalTrials.gov Identifier: NCT02722902
• Recruitment Status: Terminated
• First Posted: March 30, 2016
• Last Update Posted: April 26, 2018
• Sponsor: Maastricht University Medical Center
• Information provided by (Responsible Party): Maastricht University Medical Center

Study Description

Brief Summary:

Insulin resistant subjects and type 2 diabetic patients are characterized by a decreased metabolic flexibility: a reduced capability to switch from fat oxidation in the basal state to carbohydrate oxidation in the insulin-stimulated state. This metabolic inflexibility is an early hallmark in the development of diabetes. Recent evidence suggests that a low carnitine availability may limit acetylcarnitine formation, thereby reducing metabolic flexibility. Thus, when substrate flux in the muscle is high, acetyl-CoA concentrations increase, leading to inhibition of pyruvate dehydrogenase (PDH) and thereby reducing glucose oxidation. The conversion of acetyl-CoA to acetylcarnitine relieves this acetyl-CoA pressure on PDH. To provide more direct insight into the effect of carnitine in preventing metabolic inflexibility and insulin resistance and to further explore the mechanism of action is the focus of this research. Here, we hypothesize that the capacity to form acetylcarnitine may rescue lipid-induced insulin resistance. To this end, insulin resistance will be induced by lipid infusion in healthy volunteers and it will be tested whether carnitine co-infusion can alleviate insulin resistance.

Condition or disease	Intervention/treatment	Phase
Glucose Intolerance	Drug: Carnitor; Dietary Supplement: IntraLipid; Dietary Supplement: Placebo	Not Applicable

Detailed Description:

Rationale: Insulin resistant subjects and type 2 diabetic patients are characterized by a decreased metabolic flexibility: a reduced capability to switch from fat oxidation in the basal state to carbohydrate oxidation in the insulin-stimulated state. This metabolic inflexibility is an early hallmark in the development of diabetes. Recent evidence suggests that a low carnitine availability may limit acetylcarnitine formation, thereby reducing metabolic flexibility. Thus, when substrate flux in the muscle is high, acetyl-CoA concentrations increase, leading to inhibition of pyruvate dehydrogenase (PDH) and thereby reducing glucose oxidation. The conversion of acetyl-CoA to acetylcarnitine relieves this acetyl-CoA pressure on PDH. To provide more direct insight into the effect of carnitine in preventing metabolic inflexibility and insulin resistance and to further explore the mechanism of action is the focus of this research. Here, we hypothesize that the capacity to form acetylcarnitine may rescue lipid-induced insulin resistance. To this end, insulin resistance will be induced by lipid infusion in healthy volunteers and it will be tested whether carnitine co-infusion can alleviate insulin resistance.

Objective: The primary objectives are to investigate whether L-carnitine infusion may rescue lipid-induced insulin resistance and whether L-carnitine infusion is improving metabolic flexibility in the state of lipid-induced insulin resistance. Furthermore, a secondary objective is to examine the molecular pathways of carnitine and acetylcarnitine, responsible for muscle insulin sensitivity.

Study design: The current study is an interventional randomized crossover trial in which each subject serves as it owns control. Subjects will be blinded for the intervention.

Study population: n=10, healthy young (18-40 years) male subjects will be included.

Intervention (if applicable): Ten healthy subject will be subjected to the intervention of L-carnitine infusion. To investigate whether L-Carnitine infusion may rescue lipid induced insulin resistance and improve metabolic flexibility three intervention trials are included. The first trial includes lipid infusion combined with L-Carnitine infusion (=LIPID + CAR). In the second trial, L-carnitine infusion will be replaced by placebo infusion in the form of saline (= LIPID + PLAC) in order to investigate the effect of L-Carnitine. During the third trial, lipid infusion will be replaced by infusion of saline and will serve as a control for the lipid infusion (=SALINE + PLAC) and is necessary to investigate to what extend L-carnitine can rescue lipid induced insulin resistance. All three trials will be separated by at least one week. Subjects will be blinded, so no information about the infused substances will be provided to them. The three different trials will be allocated in a random order.

Main study parameters/endpoints: The primary study endpoint is whole body insulin sensitivity, measured by the hyperinsulinemic-euglycemic clamp. Secondary endpoints are maximal acetylcarnitine concentrations after exercise, metabolic compounds in the blood and measurements regarding skeletal muscle metabolism in skeletal muscle tissue obtained by needle biopsies.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 17 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Masking: Single (Participant)
• Primary Purpose: Prevention
• Official Title: Impact of L-Carnitine Infusion on Lipid Induced Insulin Resistance
• Actual Study Start Date: May 2016
• Actual Primary Completion Date: June 2017
• Actual Study Completion Date: June 2017

Arms and Interventions

Arm	Intervention/treatment
Experimental: LIPID + Carnitor; intravenous Lipid infusion (IntraLipid) combined with carnitor (L-carnitine) infusion L-Carnitine will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The administration will start with a bolus of 15mg/kg for 10 minutes. Subsequently, continuous L-carnitine infusion of 10mg/kg will start for the remaining 350 minutes. Intralipid will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The maximum dosage will not exceed 90 mL/h.	Drug: Carnitor; CARNITOR® (levocarnitine) is a carrier molecule in the transport of long-chain fatty acids L-Carnitine will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The administration will start with a bolus of 15mg/kg for 10 minutes. Subsequently, continuous L-carnitine infusion of 10mg/kg will start for the remaining 350 minutes. across the inner mitochondrial membrane.; Other Name: L-Carnitine or Levocarnitine; Dietary Supplement: IntraLipid; Lipid emulsion for infusion
Placebo Comparator: LIPID + PLAC; Intravenous Lipid infusion (IntraLipid) combined with placebo infusion (saline) Intralipid will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The maximum dosage will not exceed 90 mL/h.	Dietary Supplement: IntraLipid; Lipid emulsion for infusion; Dietary Supplement: Placebo; Saline will be used as placebo; Other Name: saline
Placebo Comparator: PLAC; Infusion of saline (no IntraLipid and no carnitor) Saline will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The maximum dosage will not exceed 90 ml/h.	Dietary Supplement: Placebo; Saline will be used as placebo; Other Name: saline

Outcome Measures

Primary Outcome Measures :

1. Whole body insulin sensitivity [ Time Frame: 6 hours ]

   measured as GIR in µmol/kg/min during the stable period of the insulin phase of the clamp.

   • Peripheral insulin sensitivity measured as Rd in µmol/kg/min
2. Metabolic flexibility [ Time Frame: 6-hours ]
   Change in RER comparing basal and insulin stimulated state during the clamp

Secondary Outcome Measures :

1. Maximal acetylcarnitine concentrations after exercise [ Time Frame: 45 minutes ]
   Measured using 1H-MRS after 30 minutes of cycling at 70% Wmax
2. glucose concentration in the blood before and during insulin stimulation [ Time Frame: 6 hours ]
   glucose concentration in the plasma will be measured via a blood draw
3. Carnitine acyltransferase (CRaT) enzyme activity (physiological parameter) [ Time Frame: 6 hours ]

   CRaT activity will be measured in obtained muscle biopsies from the vastus Lateralis muscle using enzyme Activity Assays.

   Measurements will be obtained using 10 ml of sample incubated in 190 ml reaction buffer (50mM Tris-HCl, 1M EDTA, 0.45mM acetyl-CoA, 0.1mM DTNB; pH = 7.8). CrAT specific activity will be determined by measuring the rate of reduction of DTNB (412 nm) by the free CoA liberated from acetylCoA after adding 5mM L-carnitine and monitoring for 10 min

4. Acylcarnitine profile in the muscle (physiological parameter) [ Time Frame: 6 hours ]
   In muscle tissue obtained via biopsies. Acylcarnitine measurements will be performed using flow injection tandem mass spectrometry
5. Lipid levels (physiological parameter) [ Time Frame: 6 hours ]
   In muscle tissue obtained via biopsies
6. free fatty acid in the blood before and during insulin stimulation [ Time Frame: 6 hours ]
   free fatty acid concentration in the plasma will be measured via a blood draw
7. Triglycerides in the blood before and during insulin stimulation [ Time Frame: 6 hours ]
   Triglycerides wil be measured in the plasma via a blood draw
8. Insulin in the blood before and during insulin stimulation [ Time Frame: 6 hours ]
   Insulin wil be measured in the plasma via a blood draw

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 40 Years (Adult)
• Sexes Eligible for Study: Male
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• • Caucasian

  • Healthy (as determined by responsible physician based on a medical questionnaire)
  • Male
  • Age: 18-40 years
  • Normal BMI: 18-25 kg/m2
  • Stable dietary habits
  • No use of medication interfering with investigated study parameters (as determined by responsible physician)

Exclusion Criteria:

• • Female

  • Haemoglobin levels < 7.8 mmol/L
  • Uncontrolled hypertension
  • Use of anticoagulants
  • Engagement in exercise > 3 hours a week
  • Being vegetarian or vegan (because of altered whole body carnitine status)
  • Smoking
  • Alcohol and/or drug abuse
  • Unstable body weight (weight gain or loss > 5kg in the last 3 months)
  • Significant food allergies/intolerances (seriously hampering study meals)
  • Participation in another biomedical study within 1 month before the first study visit, which would possibly hamper our study results
  • Medication use known to hamper subject's safety during the study procedures
  • Medication use known to interfere with investigated study parameters
  • Subjects with contra-indications for MRI
  • Subjects who intend to donate blood during the intervention or subjects who have donated blood less than three months before the start of the study
  • Subjects who do not want to be informed about unexpected medical findings
  • Subjects who do not want that their treating physician is informed

Contacts and Locations

Locations

Netherlands

Maastricht University Medical Center

Maastricht, Limburg, Netherlands, 6229 ER

Sponsors and Collaborators

Maastricht University Medical Center

Investigators

• Principal Investigator: Vera B Schrauwen, Dr; Maastricht University Medical Center

More Information

• Responsible Party: Maastricht University Medical Center
• ClinicalTrials.gov Identifier: NCT02722902
• Other Study ID Numbers: NL56319.068.16
• First Posted: March 30, 2016
• Last Update Posted: April 26, 2018
• Last Verified: July 2017

Keywords provided by Maastricht University Medical Center:

Metabolic flexibility; Insulin sensitivity

Additional relevant MeSH terms:

Insulin Resistance; Glucose Intolerance; Hyperinsulinism; Glucose Metabolism Disorders; Metabolic Diseases; Hyperglycemia; Soybean oil, phospholipid emulsion; Fat Emulsions, Intravenous; Parenteral Nutrition Solutions; Pharmaceutical Solutions